Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30857688 | 0.87 | PTGS2 (0.41) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL19839299 | 0.82 | PTGS2 (0.40) | PTGS2PTGS1BCL2L1GFERSLC6A3 | |
| SCHEMBL25215204 | 0.81 | BCL2L1 (0.51) | PTGS2PTGS1BCL2L1GFERBCL2 | |
| SCHEMBL15538598 | 0.81 | PTGS2 (0.36) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL22325211 | 0.76 | BCL2L1 (0.40) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL26648644 | 0.76 | BCL2L1 (0.40) | PTGS2PTGS1BCL2L1BCL2SLC6A3 | |
| SCHEMBL19839443 | 0.76 | PTGS2 (0.38) | PTGS2PTGS1 | |
| SCHEMBL25586183 | 0.74 | SLC6A3 (0.44) | PTGS2PTGS1GFERSLC6A3 | |
| SCHEMBL15539299 | 0.73 | PTGS2 (0.44) | PTGS2PTGS1BCL2L1SLC6A3 | |
| SCHEMBL1959392 | 0.73 | PTGS2 (0.45) | PTGS2PTGS1BCL2L1GFERBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| EP-4194454-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| EP-4194454-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | Beijing InnoCare Pharma Tech Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271959-A1 | HETEROCYCLIC COMPOUND AS BCL-2 INHIBITOR | BCL2, BCL2L11, BCL2L2 | PTGS2 180/4885PTGS1 448/4885BCL2L1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.